BACKGROUND Dry eye syndrome(DES)after diabetic cataract surgery can seriously affect the patient’s quality of life.Therefore,effective alleviation of symptoms in patients with this disease has important clinical sign...BACKGROUND Dry eye syndrome(DES)after diabetic cataract surgery can seriously affect the patient’s quality of life.Therefore,effective alleviation of symptoms in patients with this disease has important clinical significance.AIM To explore the clinical effect of recombinant human epidermal growth factor(rhEGF)plus sodium hyaluronate(SH)eye drops on DES after cataract surgery in patients with diabetes.METHODS We retrospectively evaluated 82 patients with diabetes who experienced DES after cataract surgery at Tianjin Beichen Hospital,Affiliated Hospital of Nankai University between April 2021 and April 2023.They were classified into an observation group(42 cases,rhEGF+SH eye drops)and a control group(40 cases,SH eye drops alone),depending on the different treatment schemes.The therapeutic efficacy,dry eye symptom score,tear film breakup time(TFBUT),basic tear secretion score[assessed using Schirmer I test(SIt)],corneal fluorescein staining(FL)score,tear inflammatory markers,adverse reactions during treat-ment,and treatment satisfaction were compared between the two groups.RESULTS Therapeutic efficacy was higher in the observation group compared with the control group.Both groups showed improved TFBUT and dry eye,as well as improved SIt and FL scores after treatment,with a more pronounced improvement in the observation group.Although no marked differences in adverse reactions were observed between the two groups,treatment satisfaction was higher in the observation group.CONCLUSION rhEGF+SH eye drops rendered clinical benefits to patients by effectively ameliorating dry eye and visual impairment with favorable efficacy,fewer adverse reactions,and high safety levels.Thus,this treatment should be promoted in clinical practice.展开更多
AIM: Epidermal growth factor (EGF) plays an important role in the regulation of gastrointestinal tissue growth and development, and it can stimulate epithelial proliferation, cell differentiation and growth. It has be...AIM: Epidermal growth factor (EGF) plays an important role in the regulation of gastrointestinal tissue growth and development, and it can stimulate epithelial proliferation, cell differentiation and growth. It has been established that the EGF can promote gastric cytoprotection and ulcer healing. But the potential ability of EGF to regulate the gastric cancer growth is unknown. This study is to investigate the influence of EGF on human gastric cancer cell and the implanted tumor growth of nude mice. METHODS: The cell growth rates of human gastric adenocarcinoma cell lines MKN-28, MKN-45, SGC-7901 and normal human gastric epithelial cells 3T3 were assessed when incubated with recombinant human EGF (rhEGF, 0.05, 0.1, 0.5, 1.0, 10, 50, 100 mg.L(-1)) using MTT method. The cells of MKN-28, MKN-45, SGC-7901 (gastric cancer tissue 1.5mm(3)) were implanted in the BALB/cA nude mice for 10 days.The EGF was given intraperitoneally (15, 30, 60 microg.kg(-1)) for 3 weeks. The body weights of the tumor-bearing animals and their tumor mass were measured afterwards to assess the mitogenic effect of rhEGF in the nude mice. RESULTS: Within the concentration range of 0.05-100mg.L(-1), rhEGF could increase the cell growth of normal 3T3 cells (cell growth rate 100% vs 102.8%, P【0.05), but partially restrain the gastric cancer cell growth. The latter effect was related to cell differentiation. In 15-60 microg/kg rhEGF groups, the mean implanted tumor mass of MKN-28 cell were 1.75 g, 1.91 g, 2.08 g/NS group 1.97 g (P】0.05), the mean tumor mass of SGC-7901 cell were 1.53 g, 1.07 g, 1.20 g/NS group 1.07 g (P】0.05), and for MKN-45 cell, the tumor mass were respectively 1.92 g, 1.29 g, 1.77 /NS group 1.82 g (P】0.05). So rhEGF had no obvious effect on implanted MKN-28, SGC-7901 and MKN-45 tumor growth. CONCLUSION: EGF has no stimulating effect on the human gastric cancer cell growth neither in vitro nor in vivo.展开更多
The human epidermal growth factor gene was synthesized with DNA synthesizer andby enzymes.Computer assisted to design the gene sequence and the restriction enzyme sites,andto elhninate the repeated and self-complement...The human epidermal growth factor gene was synthesized with DNA synthesizer andby enzymes.Computer assisted to design the gene sequence and the restriction enzyme sites,andto elhninate the repeated and self-complementary sequences.So that multiple doning and gene ex-pression were available for the designed gene sequence.The whole gene was formed by annealing8 chemically synthesized oligodeoxynucleotide fragments,enzymatically filling up the 4 twenty-basespaces and ligating the nicks,and was inserted into EcoR I and HInc Ⅱ sites ofplasmid pUC12.The recombinant plasmid was transformed into E.coli JM103 and 200 whitedones were obtained by X-gal and ampicilin screening.The positive clones were isolated andcharacterized by restriction enzyme analysis and DNA sequencing.展开更多
In this study the w/o/w extraction–evaporation technique was adopted to prepare poly(lactic-co-glycolic acid) (PLGA) microspheres loading recombinant human epidermal growth factor (rhEGF). The micro-spheres were char...In this study the w/o/w extraction–evaporation technique was adopted to prepare poly(lactic-co-glycolic acid) (PLGA) microspheres loading recombinant human epidermal growth factor (rhEGF). The micro-spheres were characterized for morphology by transmission electron microscopy (TEM) and particle size distribution. The release performances, the proliferation effects and therapeutic effects of rhEGF-loaded PLGA microspheres were all studied. The results showed that these spherical micro-spheres had a narrow size distribution and a high drug encapsulation efficiency (85.6%). RhEGF-loaded microspheres enhanced the growth rate of fibroblasts and wound healing more efficiently than pure rhEGF. The number of the proliferating cell nuclear antigen (PCNA) in the epidermis layer with the mi-crosphere treatment was significantly larger than those of the control groups. Overall locally sustained delivery of rhEGF from biodegradable PLGA microspheres may serve as a novel therapeutic strategy for diabetic ulcer repair.展开更多
目的:探讨卡波姆眼用凝胶联合重组人表皮生长因子(recombinant human epidermal growth factor,rhEGF)对糖尿病患者白内障术后干眼症的临床疗效。方法:选择糖尿病患者白内障超声乳化术后干眼症160例160眼,随机分为对照组80例80眼和试验...目的:探讨卡波姆眼用凝胶联合重组人表皮生长因子(recombinant human epidermal growth factor,rhEGF)对糖尿病患者白内障术后干眼症的临床疗效。方法:选择糖尿病患者白内障超声乳化术后干眼症160例160眼,随机分为对照组80例80眼和试验组80例80眼。试验组采用卡波姆眼用凝胶联合rhEGF,对照组采用卡波姆眼用凝胶单药治疗。在治疗前、治疗后1,4wk,记录患者干眼症状、泪膜破裂时间(BUT)、泪液分泌试验(SⅠt)及角膜荧光素染色(FL)情况并对眼部安全性进行评价。结果:治疗前试验组和对照组患者眼部主观症状及泪膜功能检测(BUT,SⅠt,FL)比较均无统计学差异(P>0.05)。治疗1wk和4wk后,两组患者眼部主观症状及泪膜功能检测(BUT,SⅠt,FL)与本组治疗前比较差异有统计学意义(P<0.01);试验组和对照组比较差异亦有统计学意义(P<0.05;P<0.01),试验组较对照组BUT明显延长(P<0.01),SⅠt浸湿滤纸长度明显增加(P<0.01)、FL着色密集度明显减少(P<0.01),所有观察病例中未发现明显不耐受药物的患者。结论:卡波姆眼用凝胶能明显改善糖尿病患者白内障术后干眼症状,恢复泪膜稳定性,与rhEGF联合治疗的疗效可能优于其单药治疗。展开更多
[目的]研究重组人表皮生长因子(recombinant human epidermal growth factor,rhEGF)在治疗外伤性鼓膜穿孔过程中的作用。[方法]对门诊就诊的外伤性鼓膜穿孔患者123例患者,随机的分别采用4种不同的治疗方法(即常规治疗方法、贴膜法、应用...[目的]研究重组人表皮生长因子(recombinant human epidermal growth factor,rhEGF)在治疗外伤性鼓膜穿孔过程中的作用。[方法]对门诊就诊的外伤性鼓膜穿孔患者123例患者,随机的分别采用4种不同的治疗方法(即常规治疗方法、贴膜法、应用rhEGF喷剂法、贴膜和rhEGF喷剂联合应用法),定期观察鼓膜愈合情况、瘢痕的轻重,记录鼓膜完全愈合的时间,按鼓膜穿孔的大、中、小,分3组进行统计学处理。[结果]对小穿孔4种治疗方法差异无显著性意义(愈合时间,P>0.05),对中等穿孔,传统组、贴膜组与rhEGF组、贴膜+rhEGF组之间分别两两比较差异有显著性意义(P<0.05)。对大穿孔,传统组、贴膜组、贴膜+rhEGF组三者之间两两比较差异均有显著性意义(P<0.05)。[结论]外伤性鼓膜穿孔中的中等穿孔和大穿孔应用rhEGF或rhEGF与贴膜联合应用,可以显著地缩短愈合时间,并减轻鼓膜瘢痕,提高治愈率。展开更多
基金Supported by Tianjin Health Research Project,No.TJWJ2023MS062。
文摘BACKGROUND Dry eye syndrome(DES)after diabetic cataract surgery can seriously affect the patient’s quality of life.Therefore,effective alleviation of symptoms in patients with this disease has important clinical significance.AIM To explore the clinical effect of recombinant human epidermal growth factor(rhEGF)plus sodium hyaluronate(SH)eye drops on DES after cataract surgery in patients with diabetes.METHODS We retrospectively evaluated 82 patients with diabetes who experienced DES after cataract surgery at Tianjin Beichen Hospital,Affiliated Hospital of Nankai University between April 2021 and April 2023.They were classified into an observation group(42 cases,rhEGF+SH eye drops)and a control group(40 cases,SH eye drops alone),depending on the different treatment schemes.The therapeutic efficacy,dry eye symptom score,tear film breakup time(TFBUT),basic tear secretion score[assessed using Schirmer I test(SIt)],corneal fluorescein staining(FL)score,tear inflammatory markers,adverse reactions during treat-ment,and treatment satisfaction were compared between the two groups.RESULTS Therapeutic efficacy was higher in the observation group compared with the control group.Both groups showed improved TFBUT and dry eye,as well as improved SIt and FL scores after treatment,with a more pronounced improvement in the observation group.Although no marked differences in adverse reactions were observed between the two groups,treatment satisfaction was higher in the observation group.CONCLUSION rhEGF+SH eye drops rendered clinical benefits to patients by effectively ameliorating dry eye and visual impairment with favorable efficacy,fewer adverse reactions,and high safety levels.Thus,this treatment should be promoted in clinical practice.
文摘AIM: Epidermal growth factor (EGF) plays an important role in the regulation of gastrointestinal tissue growth and development, and it can stimulate epithelial proliferation, cell differentiation and growth. It has been established that the EGF can promote gastric cytoprotection and ulcer healing. But the potential ability of EGF to regulate the gastric cancer growth is unknown. This study is to investigate the influence of EGF on human gastric cancer cell and the implanted tumor growth of nude mice. METHODS: The cell growth rates of human gastric adenocarcinoma cell lines MKN-28, MKN-45, SGC-7901 and normal human gastric epithelial cells 3T3 were assessed when incubated with recombinant human EGF (rhEGF, 0.05, 0.1, 0.5, 1.0, 10, 50, 100 mg.L(-1)) using MTT method. The cells of MKN-28, MKN-45, SGC-7901 (gastric cancer tissue 1.5mm(3)) were implanted in the BALB/cA nude mice for 10 days.The EGF was given intraperitoneally (15, 30, 60 microg.kg(-1)) for 3 weeks. The body weights of the tumor-bearing animals and their tumor mass were measured afterwards to assess the mitogenic effect of rhEGF in the nude mice. RESULTS: Within the concentration range of 0.05-100mg.L(-1), rhEGF could increase the cell growth of normal 3T3 cells (cell growth rate 100% vs 102.8%, P【0.05), but partially restrain the gastric cancer cell growth. The latter effect was related to cell differentiation. In 15-60 microg/kg rhEGF groups, the mean implanted tumor mass of MKN-28 cell were 1.75 g, 1.91 g, 2.08 g/NS group 1.97 g (P】0.05), the mean tumor mass of SGC-7901 cell were 1.53 g, 1.07 g, 1.20 g/NS group 1.07 g (P】0.05), and for MKN-45 cell, the tumor mass were respectively 1.92 g, 1.29 g, 1.77 /NS group 1.82 g (P】0.05). So rhEGF had no obvious effect on implanted MKN-28, SGC-7901 and MKN-45 tumor growth. CONCLUSION: EGF has no stimulating effect on the human gastric cancer cell growth neither in vitro nor in vivo.
文摘The human epidermal growth factor gene was synthesized with DNA synthesizer andby enzymes.Computer assisted to design the gene sequence and the restriction enzyme sites,andto elhninate the repeated and self-complementary sequences.So that multiple doning and gene ex-pression were available for the designed gene sequence.The whole gene was formed by annealing8 chemically synthesized oligodeoxynucleotide fragments,enzymatically filling up the 4 twenty-basespaces and ligating the nicks,and was inserted into EcoR I and HInc Ⅱ sites ofplasmid pUC12.The recombinant plasmid was transformed into E.coli JM103 and 200 whitedones were obtained by X-gal and ampicilin screening.The positive clones were isolated andcharacterized by restriction enzyme analysis and DNA sequencing.
基金the National Natural Science Foundation of China (Grant No. 50373033)the Applied Foundational Research Key Fund of Tianjin (Grant No. 05YFJZJC01001)the International Cooperative Fund of Tianjin (Grant No. 05YFGHHZ20070)
文摘In this study the w/o/w extraction–evaporation technique was adopted to prepare poly(lactic-co-glycolic acid) (PLGA) microspheres loading recombinant human epidermal growth factor (rhEGF). The micro-spheres were characterized for morphology by transmission electron microscopy (TEM) and particle size distribution. The release performances, the proliferation effects and therapeutic effects of rhEGF-loaded PLGA microspheres were all studied. The results showed that these spherical micro-spheres had a narrow size distribution and a high drug encapsulation efficiency (85.6%). RhEGF-loaded microspheres enhanced the growth rate of fibroblasts and wound healing more efficiently than pure rhEGF. The number of the proliferating cell nuclear antigen (PCNA) in the epidermis layer with the mi-crosphere treatment was significantly larger than those of the control groups. Overall locally sustained delivery of rhEGF from biodegradable PLGA microspheres may serve as a novel therapeutic strategy for diabetic ulcer repair.
文摘目的:探讨卡波姆眼用凝胶联合重组人表皮生长因子(recombinant human epidermal growth factor,rhEGF)对糖尿病患者白内障术后干眼症的临床疗效。方法:选择糖尿病患者白内障超声乳化术后干眼症160例160眼,随机分为对照组80例80眼和试验组80例80眼。试验组采用卡波姆眼用凝胶联合rhEGF,对照组采用卡波姆眼用凝胶单药治疗。在治疗前、治疗后1,4wk,记录患者干眼症状、泪膜破裂时间(BUT)、泪液分泌试验(SⅠt)及角膜荧光素染色(FL)情况并对眼部安全性进行评价。结果:治疗前试验组和对照组患者眼部主观症状及泪膜功能检测(BUT,SⅠt,FL)比较均无统计学差异(P>0.05)。治疗1wk和4wk后,两组患者眼部主观症状及泪膜功能检测(BUT,SⅠt,FL)与本组治疗前比较差异有统计学意义(P<0.01);试验组和对照组比较差异亦有统计学意义(P<0.05;P<0.01),试验组较对照组BUT明显延长(P<0.01),SⅠt浸湿滤纸长度明显增加(P<0.01)、FL着色密集度明显减少(P<0.01),所有观察病例中未发现明显不耐受药物的患者。结论:卡波姆眼用凝胶能明显改善糖尿病患者白内障术后干眼症状,恢复泪膜稳定性,与rhEGF联合治疗的疗效可能优于其单药治疗。
文摘[目的]研究重组人表皮生长因子(recombinant human epidermal growth factor,rhEGF)在治疗外伤性鼓膜穿孔过程中的作用。[方法]对门诊就诊的外伤性鼓膜穿孔患者123例患者,随机的分别采用4种不同的治疗方法(即常规治疗方法、贴膜法、应用rhEGF喷剂法、贴膜和rhEGF喷剂联合应用法),定期观察鼓膜愈合情况、瘢痕的轻重,记录鼓膜完全愈合的时间,按鼓膜穿孔的大、中、小,分3组进行统计学处理。[结果]对小穿孔4种治疗方法差异无显著性意义(愈合时间,P>0.05),对中等穿孔,传统组、贴膜组与rhEGF组、贴膜+rhEGF组之间分别两两比较差异有显著性意义(P<0.05)。对大穿孔,传统组、贴膜组、贴膜+rhEGF组三者之间两两比较差异均有显著性意义(P<0.05)。[结论]外伤性鼓膜穿孔中的中等穿孔和大穿孔应用rhEGF或rhEGF与贴膜联合应用,可以显著地缩短愈合时间,并减轻鼓膜瘢痕,提高治愈率。
